Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 29, 2007

Sanofi-aventis Inks Partnership with Regeneron Valued at $560M

  • Regeneron and sanofi-aventis inked a deal in which the latter company will pay up to $560 million as well as make an equity investment worth about $312 million.

    The firms will will jointly discover, develop, and market fully human therapeutic antibodies utilizing Regeneron’s VelociSuite of technologies.

    Under the terms of the agreement, sanofi-aventis will make an initial payment of $85 million. Regeneron will also receive $475 million in research funding over the next five years. At the end of this period, sanofi-aventis has the option of extending the agreement for another three years.

    Additionally, sanofi-aventis will increase its holdings of Regeneron stock from 4% to 19% with the purchase of 12 million newly issued shares. The company is paying $26 per share, a 51.6% increase over yesterday’s closing price of $17.15.

    An antibody, Interleukin-6 receptor (IL-6), which has already started clinical trials in rheumatoid arthritis, will be the first therapeutic to enter clinical trials under the collaboration. In 2008, a second antibody, Delta-like ligan-4 (DLL4) is scheduled to start clinical development.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »